Prudent Man Advisors LLC Purchases Shares of 1,801 Integer Holdings Corporation $ITGR

Prudent Man Advisors LLC purchased a new stake in shares of Integer Holdings Corporation (NYSE:ITGR) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,801 shares of the medical equipment provider’s stock, valued at approximately $221,000.

A number of other institutional investors have also recently added to or reduced their stakes in ITGR. Bessemer Group Inc. grew its position in Integer by 73.1% during the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 125 shares during the period. Teacher Retirement System of Texas purchased a new stake in Integer during the first quarter valued at about $579,000. Principal Financial Group Inc. grew its position in Integer by 2.8% during the first quarter. Principal Financial Group Inc. now owns 187,290 shares of the medical equipment provider’s stock valued at $22,102,000 after acquiring an additional 5,023 shares during the period. OneDigital Investment Advisors LLC grew its position in Integer by 14.1% during the first quarter. OneDigital Investment Advisors LLC now owns 1,969 shares of the medical equipment provider’s stock valued at $232,000 after acquiring an additional 243 shares during the period. Finally, TD Private Client Wealth LLC grew its position in Integer by 5.8% during the first quarter. TD Private Client Wealth LLC now owns 1,524 shares of the medical equipment provider’s stock valued at $180,000 after acquiring an additional 83 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Analyst Upgrades and Downgrades

ITGR has been the topic of a number of recent research reports. Bank of America cut Integer from a “buy” rating to a “neutral” rating and set a $87.00 price objective on the stock. in a research note on Friday. Wells Fargo & Company restated an “equal weight” rating and set a $80.00 price objective (down previously from $132.00) on shares of Integer in a research note on Friday. Argus cut Integer from a “buy” rating to a “hold” rating in a research note on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research note on Wednesday, October 8th. Finally, Truist Financial cut their price target on Integer from $121.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday. Four analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $97.75.

Integer Trading Down 1.3%

Shares of NYSE ITGR opened at $72.94 on Monday. The stock has a market capitalization of $2.56 billion, a P/E ratio of 30.52, a PEG ratio of 0.57 and a beta of 0.97. The stock’s 50 day moving average price is $103.61 and its two-hundred day moving average price is $112.45. Integer Holdings Corporation has a 52-week low of $66.50 and a 52-week high of $146.36. The company has a quick ratio of 2.45, a current ratio of 3.71 and a debt-to-equity ratio of 0.70.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, October 23rd. The medical equipment provider reported $1.79 EPS for the quarter, beating the consensus estimate of $1.68 by $0.11. The company had revenue of $467.69 million during the quarter, compared to analyst estimates of $466.45 million. Integer had a return on equity of 12.84% and a net margin of 4.75%.The business’s revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.43 earnings per share. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. On average, analysts anticipate that Integer Holdings Corporation will post 6.01 earnings per share for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.